Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other ju ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2022 Earnings Conference Call February 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Richard Francis - Chief Executive Officer Eli Kalif - Executive Vice President and Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Umer Raffat - Evercore ISI Gary Nachman - BMO Capital Markets Glen Santangelo - Jefferies Jason Gerberry - Bank ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) 41st Annual J.P. Morgan Healthcare Conference January 11, 2023 1:30 PM ET Company Participants Eli Kalif - Executive Vice President and Chief Financial Officer Richard Francis - President and CEO Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Teva this morning. From the company, we have the company's recently appointed CEO, Richard Francis; as well ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Kare Schultz - President and Chief Executive Officer Eli Kalif - Executive Vice President and Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Elliot Wilbur - Raymond James Glen Santangelo - Jefferies Umer Raffat - Evercore Jason Gerberry - Bank o ...

| --- | --- | |----------------------------------------------------------------|-------| | | | | | | | Teva Pharmaceutical Industries Ltd. Third Quarter 2022 Results | | | November 3, 2022 | | Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or or ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q2 2022 Earnings Conference Call July 27, 2022 8:00 AM ET Company Participants Ran Meir – Senior Vice President, Head of Investor Relations Kare Schultz – Chief Executive Officer Eli Kalif – Chief Financial Officer Sven Dethlefs – Executive Vice President, North America Commercial Conference Call Participants Balaji Prasad – Barclays Nathan Rich – Goldman Sachs Umer Raffat – Evercore Jason Gerberry – Bank of America Ashwani Verma – UBS Elliot Wilbur – Raymo ...

| --- | --- | |-----------------------------|-------| | | | | Second Quarter 2022 Results | | | July 27, 2022 | | Agenda 1 Opioid litigation updates 2 Second quarter 2022 results 3 Strategy update and 2027 long-term financial targets 4 Q&A teva Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to ...

Revenue Performance - Revenues for the second quarter of 2022 were $3,786 million, a decrease of 3% compared to the second quarter of 2021, but an increase of 1% in local currency terms [284]. - North America segment revenues were $1,904 million, a decrease of 2% compared to the second quarter of 2021, with a profit of $481 million, down 8% [286]. - Europe segment revenues were $1,171 million, a decrease of 1% in U.S. dollars but an increase of 8% in local currency terms, with a profit increase of 13% [286]. - International Markets segment revenues were $454 million, a decrease of 6% in U.S. dollars but an increase of 3% in local currency terms, with a profit decrease of 23% [286]. - Total revenues for the company in Q2 2022 were $3,786 million, a decrease of 3% compared to $3,903 million in Q2 2021 [360]. - Total revenues for the company decreased by 6% to $7,447 million in the first six months of 2022, primarily due to lower revenues from COPAXONE and generic products [435]. Profitability - Operating loss was $949 million in the second quarter of 2022, compared to an operating income of $582 million in the second quarter of 2021 [286]. - Net loss attributable to Teva in Q2 2022 was $232 million, compared to net income of $207 million in Q2 2021 [387]. - Operating loss was $1,662 million in the first six months of 2022, compared to operating income of $1,015 million in the first six months of 2021, representing an operating loss as a percentage of revenues of 22.3% [451]. - Net loss attributable to Teva was $1,187 million in the first six months of 2022, compared to net income of $284 million in the first six months of 2021 [456]. Segment Performance - Generic products revenues in North America were $1,026 million, an increase of 8% compared to the second quarter of 2021, mainly due to revenues from lenalidomide capsules [291]. - Revenues from the North America segment for BENDEKA and TREANDA decreased by 22% to $83 million in Q2 2022 compared to Q2 2021, primarily due to competition from alternative therapies [301]. - COPAXONE revenues in North America decreased by 38% to $94 million in Q2 2022 compared to Q2 2021, driven by generic competition and reduced market share [306]. - AJOVY revenues in the Europe segment increased by 52% to $29 million in Q2 2022, up from $19 million in Q2 2021 [330]. - AJOVY revenues in the International Markets segment increased by 96% to $10 million in Q2 2022, compared to $5 million in Q2 2021 [348]. Expenses - R&D expenses for the North America segment in Q2 2022 were $147 million, down 10% from $162 million in Q2 2021 [319]. - R&D expenses in Q2 2022 were $228 million, an 8% decrease from Q2 2021, representing 6.0% of revenues compared to 6.3% in the prior year [365][368]. - S&M expenses in Q2 2022 were $594 million, a 3% decrease from Q2 2021, maintaining 15.7% of revenues for both periods [373]. - G&A expenses in Q2 2022 were $313 million, a 29% increase from Q2 2021, representing 8.3% of revenues compared to 6.2% in the prior year [374][375]. - R&D expenses for the Europe segment were $56 million in Q2 2022, a decrease of 11% from $63 million in Q2 2021 [338]. Balance Sheet and Debt - As of June 30, 2022, total debt was $22,082 million, a decrease from $23,043 million as of December 31, 2021 [286]. - Total balance sheet assets decreased to $45,932 million as of June 30, 2022, down from $47,666 million as of December 31, 2021 [463]. - Total equity was $9,828 million as of June 30, 2022, a decrease from $11,244 million as of December 31, 2021, primarily due to a net loss and negative currency impacts [473]. - Debt decreased to $22,082 million as of June 30, 2022, from $23,043 million as of December 31, 2021, mainly due to exchange rate fluctuations and senior notes repayment [468]. Currency and Exchange Rate Impact - Approximately 47% of revenues in Q2 2022 were denominated in currencies other than the U.S. dollar, exposing the company to significant foreign currency risks [390]. - Exchange rate movements negatively impacted overall revenues by $162 million and operating income by $6 million in Q2 2022 compared to Q2 2021 [392]. - Approximately 48% of revenues were denominated in currencies other than the U.S. dollar, exposing the company to significant foreign currency risks [458].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...